EXANE DERIVATIVES - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.

Quarter-by-quarter ownership
EXANE DERIVATIVES ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q4 2021$54,141,000
-48.6%
3,246
+44.5%
0.01%
-48.0%
Q3 2021$105,313,000
-34.6%
2,247
-12.5%
0.02%
-32.4%
Q2 2021$161,087,000
+59.7%
2,568
+56.8%
0.04%
+27.6%
Q1 2021$100,896,000
+186.7%
1,638
+230.9%
0.03%
+190.0%
Q4 2020$35,198,0004950.01%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q4 2020
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$160,016,45665.94%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$819,077,80528.79%
Cormorant Asset Management, LP 4,662,530$122,950,9167.17%
Frazier Life Sciences Management, L.P. 2,725,949$71,883,2754.77%
Octagon Capital Advisors LP 971,639$25,622,1203.94%
M28 Capital Management LP 121,200$3,196,0443.66%
VIKING GLOBAL INVESTORS LP 25,120,991$662,440,5332.69%
BOONE CAPITAL MANAGEMENT LLC 313,381$8,263,8572.61%
Fernwood Investment Management, LLC 235,620$6,213,2992.23%
SOUTHPORT MANAGEMENT, L.L.C. 15,000$395,5502.15%
View complete list of BRIDGEBIO PHARMA INC shareholders